CymaBay Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

CymaBay Therapeutics

12/05/2023 22:54

* CymaBay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 15. 
    * The Newark California California-based  company is
expected to
report revenue of $21.35 million, according to the mean estimate
from 8 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for CymaBay
Therapeutics Inc
is for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for CymaBay
Therapeutics Inc is $13.5​, above​ its last closing price
of $10.29. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.30       -0.30      -0.30     Met     0
 Sep. 30 2022  -0.30       -0.30      -0.28     Beat    7
 Jun. 30 2022  -0.30       -0.30      -0.31     Missed  -3.8​
 Mar. 31 2022  -0.31       -0.31      -0.32     Missed  -3.3
 ​​Dec.                    -0.26      -0.34     Missed  -30.1
 31 2021                                                
 Sep. 30 2021  -0.28       -0.26      -0.33     Missed  -25.4​
 Jun. 30 2021  -0.27       -0.27      -0.34     Missed  -27
 Mar. 31 2021  -0.25       -0.24      -0.25     Missed  -2.4
 This summary was machine generated May 12 at 21:54 GMT.  All
figures in US dollars  unless otherwise stated